Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
-455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement.
Monraats PS, Rana JS, Zwinderman AH, de Maat MP, Kastelein JP, Agema WR, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: jukema jw. Thromb Haemost. 2005 Mar;93(3):564-9. doi: 10.1160/TH04-11-0708. Thromb Haemost. 2005. PMID: 15735811 Clinical Trial.
Genetic inflammatory factors predict restenosis after percutaneous coronary interventions.
Monraats PS, Pires NM, Agema WR, Zwinderman AH, Schepers A, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Frants RR, Quax PH, van Vlijmen BJ, Atsma DE, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: jukema jw. Circulation. 2005 Oct 18;112(16):2417-25. doi: 10.1161/CIRCULATIONAHA.105.536268. Circulation. 2005. PMID: 16230497
Tumor necrosis factor-alpha plays an important role in restenosis development.
Monraats PS, Pires NM, Schepers A, Agema WR, Boesten LS, de Vries MR, Zwinderman AH, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, 't Hart LM, Frants RR, Quax PH, van Vlijmen BJ, Havekes LM, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: jukema jw. FASEB J. 2005 Dec;19(14):1998-2004. doi: 10.1096/fj.05-4634com. FASEB J. 2005. PMID: 16319143
Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1.
Wijpkema JS, van Haelst PL, Monraats PS, Bruinenberg M, Zwinderman AH, Zijlstra F, van der Steege G, de Winter RJ, Doevendans PA, Waltenberger J, Jukema JW, Tio RA. Wijpkema JS, et al. Among authors: jukema jw. Pharmacogenet Genomics. 2006 May;16(5):331-7. doi: 10.1097/01.fpc.0000205001.07054.fa. Pharmacogenet Genomics. 2006. PMID: 16609364
Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention.
Monraats PS, Kurreeman FA, Pons D, Sewgobind VD, de Vries FR, Zwinderman AH, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Huizinga TW, Eefting D, Quax PH, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: jukema jw. Genes Immun. 2007 Jan;8(1):44-50. doi: 10.1038/sj.gene.6364343. Epub 2006 Nov 23. Genes Immun. 2007. PMID: 17122782
The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions.
Pons D, Monraats PS, de Maat MP, Pires NM, Quax PH, van Vlijmen BJ, Rosendaal FR, Zwinderman AH, Doevendans PA, Waltenberger J, de Winter RJ, Tio RA, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. Pons D, et al. Among authors: jukema jw. Thromb Haemost. 2007 Dec;98(6):1323-8. Thromb Haemost. 2007. PMID: 18064331
1,130 results